After 2 years of a maturing regulatory landscape for companion diagnostics and IVD in Europe, the emergence of new technologies including AI/ML, next generation sequencing and genetic-based diagnostics, coupled with a plethora of groundbreaking collaborations and CE-mark approvals, has led to an inflection point in which personalised medicines for all patients is now on the horizon in Europe.

As such the 14th Clinical Biomarkers & Companion Diagnostics Summit Europe returns as the leading forum for drug developers, diagnostics providers, and regulatory professionals to accelerate the development of drug-diagnostics in diseases with unmet medical need. With a revamped track design, 2024 has 2 streams dedicated to: Biomarker Discovery & Development and Drug-Dx Development & Commercialisation to propel your development.

Join 180+ senior executives across Biomarkers, Translational Medicine, Precision Medicine & Companion Diagnostics working on modalities such as gene therapy & protein degradation, and novel biomarkers such as cfDNA & circulating histones amongst many others, for an all-encompassing thought leadership meeting where you can walk away with actionable insights and meaningful connections to successfully co-develop a European regulatory compliant CDx based precision medicine drug to improve patient outcomes.

Event Link here.